146 related articles for article (PubMed ID: 28548552)
1. Serum CYR61 Is Associated with Disease Activity in Graves' Orbitopathy.
Woo YJ; Seo Y; Kim JJ; Kim JW; Park Y; Yoon JS
Ocul Immunol Inflamm; 2018; 26(7):1094-1100. PubMed ID: 28548552
[TBL] [Abstract][Full Text] [Related]
2. Association of BTG2, CYR61, ZFP36, and SCD gene polymorphisms with Graves' disease and ophthalmopathy.
Planck T; Shahida B; Sjögren M; Groop L; Hallengren B; Lantz M
Thyroid; 2014 Jul; 24(7):1156-61. PubMed ID: 24780075
[TBL] [Abstract][Full Text] [Related]
3. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin Inhibits CYR61 Expression in Orbital Fibroblasts in Graves' Ophthalmopathy through the Regulation of FoxO3a Signaling.
Wei YH; Liao SL; Wang CC; Wang SH; Tang WC; Yang CH
Mediators Inflamm; 2021; 2021():8888913. PubMed ID: 33542676
[TBL] [Abstract][Full Text] [Related]
5. Proinflammatory Effects of Calprotectin in Graves' Orbitopathy.
Kim JW; Ko J; Kim J; Yoon JS
Ocul Immunol Inflamm; 2020; 28(1):156-163. PubMed ID: 30452877
[No Abstract] [Full Text] [Related]
6. Serum CYR61 Levels are Associated with Graves' Ophthalmopathy and Smoking in Patients with Graves' Disease.
Cerri P; Shahida B; Lantz M; Planck T
Horm Metab Res; 2022 Mar; 54(3):168-174. PubMed ID: 35276742
[TBL] [Abstract][Full Text] [Related]
7. Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Graves' orbitopathy.
Yoon JS; Chae MK; Jang SY; Lee SY; Lee EJ
Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5921-9. PubMed ID: 22871832
[TBL] [Abstract][Full Text] [Related]
8. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
9. Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves' orbitopathy.
Cheng KC; Wu YJ; Cheng KH; Cheng KY; Chen KJ; Wu WC; Lee PY; Chang CH
Graefes Arch Clin Exp Ophthalmol; 2018 Jun; 256(6):1195-1201. PubMed ID: 29397435
[TBL] [Abstract][Full Text] [Related]
10. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
[TBL] [Abstract][Full Text] [Related]
11. The potential markers involved in newly diagnosed graves' disease and the development of active graves' orbitopathy.
He M; Wang Y; Wang J; Sui J; Ding X; Chen Z; Zhang M; Zhao Y; Xie B; Shi B
Cytokine; 2020 Mar; 127():154998. PubMed ID: 31972501
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy.
Kapelko-Słowik K; Słowik M; Szaliński M; Dybko J; Wołowiec D; Prajs I; Bohdanowicz-Pawlak A; Biernat M; Urbaniak-Kujda D
Adv Clin Exp Med; 2018 Jan; 27(1):99-103. PubMed ID: 29521049
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of immediate early genes in active Graves' ophthalmopathy.
Lantz M; Vondrichova T; Parikh H; Frenander C; Ridderstråle M; Asman P; Aberg M; Groop L; Hallengren B
J Clin Endocrinol Metab; 2005 Aug; 90(8):4784-91. PubMed ID: 15928252
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of human orbital fibroblasts cultivated from intraconal, nasal and central adipose tissues.
Kim JA; Ahn D; Kim BY; Choi YJ; Shin HJ; Jang SY
Br J Ophthalmol; 2021 Feb; 105(2):290-296. PubMed ID: 31488432
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress and antioxidant activity in orbital fibroadipose tissue in Graves' ophthalmopathy.
Hondur A; Konuk O; Dincel AS; Bilgihan A; Unal M; Hasanreisoglu B
Curr Eye Res; 2008 May; 33(5):421-7. PubMed ID: 18568878
[TBL] [Abstract][Full Text] [Related]
16. Graves' orbitopathy, idiopathic orbital inflammatory pseudotumor and Epstein-Barr virus infection: a serological and molecular study.
Leo M; Maggi F; Dottore GR; Casini G; Mazzetti P; Pistello M; Sellari-Franceschini S; Nardi M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2017 May; 40(5):499-503. PubMed ID: 27987077
[TBL] [Abstract][Full Text] [Related]
17. Comparative assessment of Graves' disease and main extrathyroidal manifestation, Graves' ophthalmopathy, by non-targeted metabolite profiling of blood and orbital tissue.
Ji DY; Park SH; Park SJ; Kim KH; Ku CR; Shin DY; Yoon JS; Lee DY; Lee EJ
Sci Rep; 2018 Jun; 8(1):9262. PubMed ID: 29915201
[TBL] [Abstract][Full Text] [Related]
18. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
[TBL] [Abstract][Full Text] [Related]
19. miR-199a Downregulation as a Driver of the NOX4/HIF-1α/VEGF-A Pathway in Thyroid and Orbital Adipose Tissues from Graves' Patients.
Craps J; Joris V; Baldeschi L; Daumerie C; Camboni A; Buemi A; Lengelé B; Behets C; Boschi A; Mourad M; Many MC; Dessy C
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008579
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory effect of quercetin in a whole orbital tissue culture of Graves' orbitopathy.
Yoon JS; Chae MK; Lee SY; Lee EJ
Br J Ophthalmol; 2012 Aug; 96(8):1117-21. PubMed ID: 22661653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
